Total for the last 12 months
number of access : ?
number of downloads : ?
ID 119253
Author
Kitamura, Naoya Kochi University
Sento, Shinya Kochi University
Yoshizawa, Yasumasa Kochi University
Sasabe, Eri Kochi University
Yamamoto, Tetsuya Kochi University
Keywords
head and neck squamous cell carcinoma
molecular targeted therapy
cetuximab
immune checkpoint inhibitor
multi-oncogene panel test
photoimmunotherapy
Content Type
Journal Article
Description
In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and paclitaxel), epidermal growth factor receptor-tyrosine kinase inhibitors (cetuximab) and immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) antibodies (nivolumab and pembrolizumab) have come to be used. The importance of anti-cancer drug therapy is increasing year by year. Therefore, we summarize clinical trials of molecular targeted therapy and biomarkers in HNSCC from previous studies. Here we show the current trends and future prospects of molecular targeted therapy in HNSCC.
Journal Title
International Journal of Molecular Sciences
ISSN
14220067
Publisher
MDPI
Volume
22
Issue
1
Start Page
240
Published Date
2020-12-29
Rights
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Oral Sciences